References
1.Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N Engl J Med. 1999 Sep 16;341(12):910-1. doi: 10.1056/NEJM199909163411209. PMID: 10486424
2.Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370–2375. doi: 10.1001/jama.285.18.2370
3.Walters, T. E., Wick, K., Tan, G., Mearns, M., Joseph, S. A., Morton, J. B., … & Kalman, J. M. (2018). Psychological distress and suicidal ideation in patients with atrial fibrillation: prevalence and response to management strategy. Journal of the American Heart Association, 7(18), e005502.
4.Calkins H, Kuck KH, Cappato R, et al. HRS/EHRA/ECAS expertconsensus statement on catheter and surgical ablation of atrialfibrillation: recommendations for patient selection, proceduraltechniques, patient management and follow‐up, definitions, end-points, and research trial design: a report of the heart rhythm society(HRS) task force on catheter and surgical ablation of atrial fibrillation.Developed in partnership with the European Heart Rhythm Associa-tion (EHRA), a registered branch of the European Society ofCardiology (ESC) and the European Cardiac Arrhythmia Society(ECAS); and in collaboration with the American College of Cardiology(ACC), American Heart Association (AHA), the Asia Pacific HeartRhythm Society (APHRS), and the society of thoracic surgeons (STS).Endorsed by the governing bodies of the American College ofCardiology Foundation, the American Heart Association, the Eur-opean Cardiac Arrhythmia Society, the European Heart RhythmAssociation, the Society of Thoracic Surgeons, the Asia Pacific HeartRhythm Society, and the heart rhythm society.Heart Rhythm.2012;2012(9):632‐696. e621.6.
5.Prabhu, S., Taylor, A. J., Costello, B. T., Kaye, D. M., McLellan, A. J., Voskoboinik, A., … & Kistler, P. M. (2017). Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. Journal of the American College of Cardiology, 70(16), 1949-1961.
6.Marrouche, N. F., Brachmann, J., & CASTLE‐AF Steering Committee. (2009). Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (castle‐af)‐study design. Pacing and clinical electrophysiology, 32(8), 987-994.
7.Miyazaki S, Kuwahara T, Kobori A, Takahashi Y, Takei A, Sato A, et al. Pharmacological cardioversion preceding left atrial ablation: bepridil predicts the clinical outcome following ablation in patients with persistent atrial fibrillation. Europace. 2009;11:1620–3.
8.Igarashi M, Tada H, Sekiguchi Y, Yamasaki H, Arimoto T, Kuroki K, et al. Effect of restoration of sinus rhythm by extensive anti-arrhythmic drugs in predicting results of catheter ablation of persis- tent atrial fibrillation. Am J Cardiol. 2010;106(1):62–8.
9.Benák, A., Kohári, M., Herczeg, A. et al. Selecting persistent atrial fibrillation patients for pulmonary vein isolation based on the response to amiodarone: efficacy of the “one step back” strategy. J Interv Card Electrophysiol 56, 291–297 (2019). https://doi.org/10.1007/s10840-019-00524-z
10. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagné P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000 Mar 30;342(13):913-20. doi: 10.1056/NEJM200003303421302. PMID: 10738049.
11. Kang JH, Lee DI, Kim S, Kim MN, Park YM, Ban JE, Choi JI, Lim HE, Park SW, Kim YH. Prediction of long-term outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion. J Cardiovasc Electrophysiol. 2012 Nov;23(11):1165-70. doi: 10.1111/j.1540-8167.2012.02339.x. Epub 2012 Aug 8. PMID: 22882453.
12. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S. Effects of anti-arrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation. 2003;107(10):1440–6.
13. Ashikaga K, Kobayashi T, Kimura M, Owada S, Sasaki S, Iwasa A, et al. Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrilla- tion model. Eur J Pharmacol. 2006;536(1–2):148–53.
14Slotwiner D, Steinberg J. Limited Ablation for Persistent Atrial Fibrillation Using Preprocedure Reverse Remodelling. Arrhythm Electrophysiol Rev. 2014 Aug;3(2):101-6. doi: 10.15420/aer.2014.3.2.101. Epub 2014 Aug 30. PMID: 26835074; PMCID: PMC4711510.
15. Rivard L, Hocini M, Rostock T, Cauchemez B, Forclaz A, Jadidi AS, Linton N, Nault I, Miyazaki S, Liu X, Xhaet O, Shah A, Sacher F, Derval N, Jaïs P, Khairy P, Macle L, Nattel S, Willems S, Haïssaguerre M. Improved outcome following restoration of sinus rhythm prior to catheter ablation of persistent atrial fibrillation: a comparative multicenter study. Heart Rhythm. 2012 Jul;9(7):1025-30. doi: 10.1016/j.hrthm.2012.02.016. Epub 2012 Feb 15. PMID: 22342863.
16.Yosuke Miwa, Hitoshi Minamiguchi, Anil K. Bhandari, David S. Cannom, Ivan C. Ho, Amiodarone reduces the amount of ablation during catheter ablation for persistent atrial fibrillation, EP Europace, Volume 16, Issue 7, July 2014, Pages 1007–1014,
17. Verma A, Mantovan R, Macle L, De Martino G, Chen J, Morillo CA, Novak P, Calzolari V, Guerra PG, Nair G, Torrecilla EG, Khaykin Y. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial. Eur Heart J. 2010 Jun;31(11):1344-56. doi: 10.1093/eurheartj/ehq041. Epub 2010 Mar 9. PMID: 20215126; PMCID: PMC2878965.